Tag: diagnostics

FRANKLIN LAKES, N.J., July 22, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...

Basel, 22 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its Board of Directors' decision to propose to shareholders a modernisation of Roche Holding Ltd’s capital structure for approval at the Annual General Meeting to be held on 10 March 2026 ("2026 AGM"). The proposal includes the exchange of the existing non-voting equity securities (“Genussscheine”) for participation certificates with a nominal value of CHF 0.001 each.

7th annual contest celebrates excellence in innovation HOUSTON, July 22, 2025 /PRNewswire/ -- Franchise Update Media conducted its 7th annual Franchise Innovation Awards contest this...

Original research by NEB scientists contributes to the kit's unprecedented low bias,speed, shelf life, and input range IPSWICH, Mass., July 22, 2025 /PRNewswire/ -- New England Biolabs...

The Japan in vitro diagnostics market, valued at USD 3.97 Billion in 2024, is projected to grow at a CAGR of 6.20%, reaching USD 7.24 Billion by 2034. Key growth drivers include an aging population, demand for personalized medicine, AI-integrated testing, and home-based diagnostics. Strategic partnerships and regulatory approvals boost market potential.

The Japan in vitro diagnostics market, valued at USD 3.97 Billion in 2024, is projected to grow at a CAGR of 6.20%, reaching USD 7.24 Billion by 2034. Key growth drivers include an aging population, demand for personalized medicine, AI-integrated testing, and home-based diagnostics. Strategic partnerships and regulatory approvals boost market potential.

CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide

CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide

In the independent blinded validation study, Merlin accurately identifies melanoma patients at low risk of metastatic disease, including sentinel lymph node metastasis The potential SLNB surgery...

In the independent blinded validation study, Merlin accurately identifies melanoma patients at low risk of metastatic disease, including sentinel lymph node metastasis The potential SLNB surgery...

SINGAPORE, July 22, 2025 /PRNewswire/ -- The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass...

"This research review highlights the transformative impact of artificial intelligence (AI) and the Internet of Things (IoT) across industriindustries, showcasing significant market growth, technological...

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...

NEW YORK, July 18, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global technetium-99m market is witnessing substantial...

The global exosome research market is anticipated to expand from USD 214.4 million in 2025 to USD 480.6 million by 2030, at a CAGR of 17.5%. This growth is driven by the rising need for advanced diagnostics due to the prevalence of chronic diseases like cancer and neurodegenerative disorders. Exosomes, serving as biomarkers and therapeutic delivery agents, fulfill this demand. The kits & reagents segment is expected to lead growth, aligning with the increased demand for efficient exosome research tools. North America is projected to experience the highest growth, thanks to significant government investments supporting research initiatives. Key players such as Thermo Fisher Scientific and Bio-Techne are profiled.

The global exosome research market is anticipated to expand from USD 214.4 million in 2025 to USD 480.6 million by 2030, at a CAGR of 17.5%. This growth is driven by the rising need for advanced diagnostics due to the prevalence of chronic diseases like cancer and neurodegenerative disorders. Exosomes, serving as biomarkers and therapeutic delivery agents, fulfill this demand. The kits & reagents segment is expected to lead growth, aligning with the increased demand for efficient exosome research tools. North America is projected to experience the highest growth, thanks to significant government investments supporting research initiatives. Key players such as Thermo Fisher Scientific and Bio-Techne are profiled.